DK2825181T3 - Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom - Google Patents
Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom Download PDFInfo
- Publication number
- DK2825181T3 DK2825181T3 DK13711116.7T DK13711116T DK2825181T3 DK 2825181 T3 DK2825181 T3 DK 2825181T3 DK 13711116 T DK13711116 T DK 13711116T DK 2825181 T3 DK2825181 T3 DK 2825181T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- carbon particles
- liver disease
- porous carbon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1204696.7A GB201204696D0 (en) | 2012-03-16 | 2012-03-16 | Therapy |
PCT/GB2013/050673 WO2013136094A1 (en) | 2012-03-16 | 2013-03-15 | Porous carbon particles for use in the treatment or prevention of liver disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2825181T3 true DK2825181T3 (da) | 2020-04-14 |
Family
ID=46052080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13711116.7T DK2825181T3 (da) | 2012-03-16 | 2013-03-15 | Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom |
Country Status (16)
Country | Link |
---|---|
US (1) | US9844568B2 (da) |
EP (2) | EP3650031A1 (da) |
JP (2) | JP6293680B2 (da) |
KR (2) | KR102142504B1 (da) |
CN (1) | CN104363916B (da) |
AU (1) | AU2013234099B2 (da) |
BR (1) | BR112014022810B1 (da) |
DK (1) | DK2825181T3 (da) |
EA (1) | EA038965B1 (da) |
GB (1) | GB201204696D0 (da) |
IN (1) | IN2014DN07637A (da) |
MY (1) | MY169093A (da) |
NZ (1) | NZ631429A (da) |
SG (1) | SG11201405771QA (da) |
WO (1) | WO2013136094A1 (da) |
ZA (1) | ZA201406989B (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
WO2015161200A1 (en) * | 2014-04-17 | 2015-10-22 | ImMutriX Therapeutics, Inc. | Therapeutic detoxification compositions and methods of making and using same |
TWI607765B (zh) * | 2014-08-27 | 2017-12-11 | Kureha Corp | Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents |
CA3191747A1 (en) | 2017-03-31 | 2018-10-04 | Axial Therapeutics, Inc. | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
EP3476818A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved carbon source |
EP3476817A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved amphiphilic species |
WO2019131209A1 (ja) * | 2017-12-27 | 2019-07-04 | 株式会社クラレ | 活性炭およびその製法 |
WO2020085282A1 (ja) * | 2018-10-24 | 2020-04-30 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
JP7228498B2 (ja) * | 2018-10-24 | 2023-02-24 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
JP7338993B2 (ja) * | 2019-03-06 | 2023-09-05 | 株式会社クラレ | 多孔質炭素および多孔質炭素の製造方法 |
CN113874320B (zh) * | 2019-04-16 | 2023-12-19 | 二村化学株式会社 | 活性炭吸附剂的制造方法 |
JP7061640B2 (ja) * | 2019-04-16 | 2022-04-28 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5332637B2 (da) | 1973-05-09 | 1978-09-09 | ||
JPS51151693A (en) | 1975-06-23 | 1976-12-27 | Eisai Co Ltd | Coated bead-like activated carbon for blood purification |
JPS5673542A (en) | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
JPS5731864A (en) | 1980-08-04 | 1982-02-20 | Teijin Ltd | Oral activated carbon microcapsule |
RU2177319C2 (ru) * | 1999-03-30 | 2001-12-27 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения гиперэндотоксинемии |
GB0019417D0 (en) | 2000-08-09 | 2000-09-27 | Mat & Separations Tech Int Ltd | Mesoporous carbons |
JP3522708B2 (ja) | 2001-04-11 | 2004-04-26 | 呉羽化学工業株式会社 | 経口投与用吸着剤 |
JP4311923B2 (ja) | 2002-10-07 | 2009-08-12 | 株式会社クレハ | 経口投与用肝疾患治療又は予防剤 |
DK1407772T3 (da) | 2002-10-09 | 2006-12-11 | Kureha Corp | Farmaceutisk præparat, der omfatter poröst sfærisk carbonholdigt stof, og dets anvendelse til behandling af nyre- og leversygdomme |
US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
JP3835698B2 (ja) | 2002-11-01 | 2006-10-18 | 株式会社クレハ | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 |
JP2005089306A (ja) | 2003-09-12 | 2005-04-07 | Ajinomoto Co Inc | 炎症性腸疾患治療用の経直腸投与製剤 |
JP4382629B2 (ja) | 2003-10-22 | 2009-12-16 | 株式会社クレハ | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 |
KR101135260B1 (ko) | 2003-10-22 | 2012-04-12 | 가부시키가이샤 쿠레하 | 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제 |
TWI370013B (en) * | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
TWI370012B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
JP2007045775A (ja) | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | 含水活性炭及びその製造方法 |
DE102005062160A1 (de) | 2005-12-19 | 2007-06-21 | BLüCHER GMBH | Aktivkohle für die medizinische Verwendung |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
EP2054342B1 (en) | 2006-10-09 | 2019-07-31 | British American Tobacco (Investments) Limited | Making discrete solid particles of polymeric material |
WO2008043982A2 (en) | 2006-10-09 | 2008-04-17 | British American Tobacco (Investments) Limited | Carbonising and/or activating carbonaceous material |
WO2010138519A2 (en) | 2009-05-27 | 2010-12-02 | Ocera Therapeutics, Inc. | Use of adsorbent carbon microspheres for the treatment of pruritus |
GB0921528D0 (en) * | 2009-12-09 | 2010-01-27 | Mast Carbon Internat Ltd | Carbon and its use in blood cleansing applications |
KR101820374B1 (ko) | 2010-02-23 | 2018-01-19 | 다 볼떼라 | 장 내 흡착제의 경구 전달을 위한 제형 |
JP5984352B2 (ja) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | 経口投与用医薬用吸着剤の製造方法 |
GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
-
2012
- 2012-03-16 GB GBGB1204696.7A patent/GB201204696D0/en not_active Ceased
-
2013
- 2013-03-15 KR KR1020147029083A patent/KR102142504B1/ko active IP Right Grant
- 2013-03-15 EA EA201491690A patent/EA038965B1/ru unknown
- 2013-03-15 EP EP19211615.0A patent/EP3650031A1/en active Pending
- 2013-03-15 JP JP2014561519A patent/JP6293680B2/ja active Active
- 2013-03-15 US US14/385,332 patent/US9844568B2/en active Active
- 2013-03-15 DK DK13711116.7T patent/DK2825181T3/da active
- 2013-03-15 EP EP13711116.7A patent/EP2825181B1/en active Active
- 2013-03-15 AU AU2013234099A patent/AU2013234099B2/en active Active
- 2013-03-15 SG SG11201405771QA patent/SG11201405771QA/en unknown
- 2013-03-15 NZ NZ631429A patent/NZ631429A/en unknown
- 2013-03-15 WO PCT/GB2013/050673 patent/WO2013136094A1/en active Application Filing
- 2013-03-15 BR BR112014022810-8A patent/BR112014022810B1/pt active IP Right Grant
- 2013-03-15 KR KR1020207022420A patent/KR102441934B1/ko active IP Right Grant
- 2013-03-15 IN IN7637DEN2014 patent/IN2014DN07637A/en unknown
- 2013-03-15 CN CN201380025257.6A patent/CN104363916B/zh active Active
- 2013-03-15 MY MYPI2014002656A patent/MY169093A/en unknown
-
2014
- 2014-09-25 ZA ZA2014/06989A patent/ZA201406989B/en unknown
-
2018
- 2018-02-14 JP JP2018023609A patent/JP6647570B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
MY169093A (en) | 2019-02-18 |
SG11201405771QA (en) | 2014-10-30 |
EP2825181B1 (en) | 2020-01-08 |
BR112014022810B1 (pt) | 2021-04-13 |
KR20150002675A (ko) | 2015-01-07 |
JP2018111699A (ja) | 2018-07-19 |
WO2013136094A1 (en) | 2013-09-19 |
KR102142504B1 (ko) | 2020-08-07 |
KR102441934B1 (ko) | 2022-09-08 |
NZ631429A (en) | 2016-09-30 |
AU2013234099B2 (en) | 2017-03-30 |
EP3650031A1 (en) | 2020-05-13 |
IN2014DN07637A (da) | 2015-05-15 |
AU2013234099A1 (en) | 2014-10-02 |
ZA201406989B (en) | 2015-12-23 |
JP6647570B2 (ja) | 2020-02-14 |
EP2825181A1 (en) | 2015-01-21 |
JP2015516373A (ja) | 2015-06-11 |
JP6293680B2 (ja) | 2018-03-14 |
US9844568B2 (en) | 2017-12-19 |
KR20200096991A (ko) | 2020-08-14 |
US20150064256A1 (en) | 2015-03-05 |
EA038965B1 (ru) | 2021-11-16 |
CN104363916B (zh) | 2018-09-25 |
CN104363916A (zh) | 2015-02-18 |
EA201491690A1 (ru) | 2015-02-27 |
GB201204696D0 (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2825181T3 (da) | Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom | |
DK2981274T3 (da) | Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose | |
CO7061071A2 (es) | Procesos para la preparación de (s)-1-(3-etoxi-4-metoxifenil)-2-metansulfoniletilamina | |
DK3329909T3 (da) | Fenfluramin til anvendelse i behandling af dravet syndrom | |
DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
DK2819602T3 (da) | Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme | |
DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
DK2836200T3 (da) | Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium | |
BR112014010175A2 (pt) | unidades de filtro, componentes e recursos destas e métodos de uso e construção | |
DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
DK2841097T3 (da) | Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom | |
DK3082831T3 (da) | Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol | |
DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
BR112013024401A2 (pt) | métodos e composições para o tratamento do transtorno do déficit de atenção | |
DK2838549T3 (da) | Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom | |
DK3730136T3 (da) | Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom | |
DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
DK2854850T3 (da) | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom | |
DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
DK2917231T3 (da) | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme | |
DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri |